Literature DB >> 10199357

Cholinergic therapy for Down's syndrome.

P S Kishnani, J A Sullivan, B K Walter, G A Spiridigliozzi, P M Doraiswamy, K R Krishnan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10199357     DOI： 10.1016/S0140-6736(98)05285-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  An overview and update regarding medical problems in Down syndrome.

Authors:  V Grech
Journal:  Indian J Pediatr       Date:  2001-09       Impact factor: 1.967

2.  Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

Authors:  James H Heller; Gail A Spiridigliozzi; P Murali Doraiswamy; Jennifer A Sullivan; Bythe G Crissman; Priya S Kishnani
Journal:  Am J Med Genet A       Date:  2004-10-15       Impact factor: 2.802

3.  Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.

Authors:  James H Heller; Gail A Spiridigliozzi; Blythe G Crissman; Jennifer A Sullivan; Rebecca L Eells; Jennifer S Li; P Murali Doraiswamy; K Ranga Krishnan; Priya S Kishnani
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-12       Impact factor: 2.576

Review 4.  Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors:  J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal:  J Autism Dev Disord       Date:  2007-01-13

Review 5.  Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents.

Authors:  T Burt
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 6.  Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.

Authors:  Sharon M Castellino; Nicole J Ullrich; Megan J Whelen; Beverly J Lange
Journal:  J Natl Cancer Inst       Date:  2014-07-30       Impact factor: 13.506

7.  Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.

Authors:  James H Heller; Gail A Spiridigliozzi; Jennifer A Sullivan; P Murali Doraiswamy; Ranga R Krishnan; Priya S Kishnani
Journal:  Am J Med Genet A       Date:  2003-01-15       Impact factor: 2.802

8.  Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter.

Authors:  Zhude Tu; Simon M N Efange; Jinbin Xu; Shihong Li; Lynne A Jones; Stanley M Parsons; Robert H Mach
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 9.  Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

Authors:  Christopher Christodoulou; William S MacAllister; Nancy A McLinskey; Lauren B Krupp
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  Donepezil for dementia in people with Down syndrome.

Authors:  Monica Mohan; Peter K Carpenter; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.